Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Masimo ( (MASI) ) has issued an update.
Masimo Corporation, a company known for its non-invasive monitoring technologies, announced select preliminary financial results for the fourth quarter and full-year 2024, along with estimates for its 2025 financial guidance during the J.P. Morgan Healthcare Conference on January 16, 2025. The company projects a consolidated revenue growth of 9% for the fourth quarter, with healthcare revenue up by 8% and non-healthcare revenue seeing an 11% increase. For the full year 2024, consolidated revenue growth is expected to be 2%, with healthcare revenue showing a 9% increase while non-healthcare revenue declined by 10%. Masimo also provided guidance for 2025, anticipating healthcare revenue growth between 8% to 11% and non-GAAP earnings per share between $4.90 to $5.10.
More about Masimo
YTD Price Performance: 2.08%
Average Trading Volume: 543,441
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $8.89B
For an in-depth examination of MASI stock, go to TipRanks’ Stock Analysis page.
